These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28984500)

  • 1. Ursolic acid and carvacrol may be potential inhibitors of dormancy protein small heat shock protein16.3 of Mycobacterium tuberculosis.
    Jee B; Kumar S; Yadav R; Singh Y; Kumar A; Sharma N
    J Biomol Struct Dyn; 2018 Oct; 36(13):3434-3443. PubMed ID: 28984500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small Heat Shock Protein16.3 of Mycobacterium tuberculosis: After Two Decades of Functional Characterization.
    Jee B; Singh Y; Yadav R; Lang F
    Cell Physiol Biochem; 2018; 49(1):368-380. PubMed ID: 30138912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Metabolite Ursolic Acid as an Inhibitor of Dormancy Regulator DosR of
    Jee B; Sharma PP; Goel VK; Kumar S; Singh Y; Rathi B
    Curr Comput Aided Drug Des; 2023; 19(6):425-437. PubMed ID: 36722482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations.
    Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN
    Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursolic acid as a potential inhibitor of Mycobacterium tuberculosis cytochrome bc1 oxidase-a molecular modelling perspective.
    Tembe N; Machaba KE; Ndagi U; Kumalo HM; Mhlongo NN
    J Mol Model; 2022 Jan; 28(2):35. PubMed ID: 35022913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies.
    Bhutani I; Loharch S; Gupta P; Madathil R; Parkesh R
    PLoS One; 2015; 10(3):e0119771. PubMed ID: 25789990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimycobacterial, docking and molecular dynamic studies of pentacyclic triterpenes from Buddleja saligna leaves.
    Singh A; Venugopala KN; Khedr MA; Pillay M; Nwaeze KU; Coovadia Y; Shode F; Odhav B
    J Biomol Struct Dyn; 2017 Sep; 35(12):2654-2664. PubMed ID: 28278765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges.
    Pitaloka DAE; Syaputri Y; Nurlilasari P; Khairunnisa SF; Saallah S
    Drug Des Devel Ther; 2024; 18():1969-1979. PubMed ID: 38836115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis.
    Agarwal S; Verma E; Kumar V; Lall N; Sau S; Iyer AK; Kashaw SK
    J Mol Graph Model; 2018 Aug; 83():17-32. PubMed ID: 29753941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple receptor conformers based molecular docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP reductase (InhA).
    Khan AM; Shawon J; Halim MA
    J Mol Graph Model; 2017 Oct; 77():386-398. PubMed ID: 28957755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug targeted virtual screening and molecular dynamics of LipU protein of Mycobacterium tuberculosis and Mycobacterium leprae.
    Kaur G; Pandey B; Kumar A; Garewal N; Grover A; Kaur J
    J Biomol Struct Dyn; 2019 Mar; 37(5):1254-1269. PubMed ID: 29557724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
    Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD
    Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational investigation of phytomolecules as resuscitation-promoting factor B (RpfB) inhibitors for clinical suppression of Mycobacterium tuberculosis dormancy reactivation.
    Dwivedi VD; Arya A; Sharma T; Sharma S; Patil SA; Gupta VK
    Infect Genet Evol; 2020 Sep; 83():104356. PubMed ID: 32438079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling and docking studies of O-succinylbenzoate synthase of M. tuberculosis--a potential target for antituberculosis drug design.
    Pulaganti M; Banaganapalli B; Mulakayala C; Chitta SK; C M A
    Appl Biochem Biotechnol; 2014 Feb; 172(3):1407-32. PubMed ID: 24203275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
    Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
    Saxena S; Abdullah M; Sriram D; Guruprasad L
    J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of New
    Almeleebia TM; Shahrani MA; Alshahrani MY; Ahmad I; Alkahtani AM; Alam MJ; Kausar MA; Saeed A; Saeed M; Iram S
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33923734
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparative modeling and molecular docking study on Mycobacterium tuberculosis targets involved in peptidoglycan biosynthesis.
    Fakhar Z; Naiker S; Alves CN; Govender T; Maguire GE; Lameira J; Lamichhane G; Kruger HG; Honarparvar B
    J Biomol Struct Dyn; 2016 Nov; 34(11):2399-417. PubMed ID: 26612108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dynamics simulation and binding free energy studies of novel leads belonging to the benzofuran class inhibitors of Mycobacterium tuberculosis Polyketide Synthase 13.
    Cruz JN; Costa JFS; Khayat AS; Kuca K; Barros CAL; Neto AMJC
    J Biomol Struct Dyn; 2019 Apr; 37(6):1616-1627. PubMed ID: 29633908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing the structure of Mycobacterium tuberculosis MbtA: model validation using molecular dynamics simulations and docking studies.
    Maganti L; Open Source Drug Discovery Consortium ; Ghoshal N
    J Biomol Struct Dyn; 2014; 32(2):273-88. PubMed ID: 23527569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.